Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study

BACKGROUND: Although introduction of immune checkpoint inhibitors has revolutionized the treatment of cancer, their response rates are generally low. Preclinical and early phase clinical data suggest that MEK inhibition may sensitize tumors to immune checkpoint inhibitors by upregulating tumor antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherman, E., Lee, J.L., Debruyne, P.R., Keam, B., Shin, S.J., Gramza, A., Caro, I., Amin, R., Shah, K., Yan, Y., Huddart, R., Powles, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163002/
https://www.ncbi.nlm.nih.gov/pubmed/36947985
http://dx.doi.org/10.1016/j.esmoop.2023.100877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163002/
https://www.ncbi.nlm.nih.gov/pubmed/36947985
http://dx.doi.org/10.1016/j.esmoop.2023.100877

Ejemplares similares